Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
5.78
-0.12 (-2.03%)
Mar 9, 2026, 3:58 PM EDT - Market open
Protara Therapeutics Employees
As of December 31, 2024, Protara Therapeutics had 33 total employees, including 28 full-time and 5 part-time employees. The number of employees increased by 6 or 22.22% compared to the previous year.
Employees
33
Change (1Y)
6
Growth (1Y)
22.22%
Revenue / Employee
n/a
Profits / Employee
-$1,603,061
Market Cap
309.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33 | 6 | 22.22% |
| Dec 31, 2023 | 27 | 2 | 8.00% |
| Dec 31, 2022 | 25 | -6 | -19.35% |
| Dec 31, 2021 | 31 | 4 | 14.81% |
| Dec 31, 2020 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 172 |
| Cabaletta Bio | 151 |
| X4 Pharmaceuticals | 143 |
| Nautilus Biotechnology | 124 |
| Adlai Nortye | 123 |
| C4 Therapeutics | 110 |
| Rezolute | 75 |
| Avalo Therapeutics | 23 |
TARA News
- 12 days ago - Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript - Seeking Alpha
- 13 days ago - TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 18 days ago - Protara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium - GlobeNewsWire
- 7 weeks ago - Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones - GlobeNewsWire
- 2 months ago - Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire